Introduction
============

Electrolyte disorders frequently develop in critically ill patients during course of stay in the intensive care unit (ICU). Therefore, ICU patients are routinely monitored for electrolyte disorders, and it is common practice to correct them. Hypophosphatemia is one of those frequently encountered electrolyte disorders, for which many causative factors are present in critically ill patients. It is uncertain when and how to correct hypophosphatemia, and whether correction affects outcome in critically ill patients.

We searched the literature on hypophosphatemia in ICU patients to identify the incidence, symptoms, and treatment of hypophosphatemia. We searched for answers to the following questions: (a) whether correction of hypophosphatemia is associated with improved outcome; and (b) whether a certain treatment strategy is superior.

Materials and methods
=====================

The Medline database was searched to identify articles from 1969 to 2010 containing the Medical Subjects Heading (MeSH) term \"hypophosphatemia.\" We included clinical studies and experimental trials, as well as case reports. Results were limited to articles in the English language and to articles on humans. This search yielded 1,413 articles. The Cochrane Library was also searched for current trials on hypophosphatemia, which yielded no results. All articles were screened for relevance to critically ill patients; these articles were studied in detail. Notably, articles on chronic hypophosphatemia (for example, hereditary hypophosphatemic syndromes) were excluded.

Results
=======

Phosphate metabolism and causes of hypophosphatemia in critically ill patients
------------------------------------------------------------------------------

Phosphorus is an essential element for all living cells, with different functions (Table [1](#T1){ref-type="table"}) \[[@B1]\]. The phosphate balance is a complex interplay between phosphate uptake and phosphate excretion (Figure [1](#F1){ref-type="fig"}). Normal values of the total serum phosphate level are 0.80 to 1.45 mmol/L (2.5 to 4.5 mg/dl).

###### 

Functions of phosphate

  Form                                                  Function
  ----------------------------------------------------- -------------------------------------------------------------------------
  Hydroxyapatite                                        Bone structure
  Phospholipids                                         Structure of cell membranes
  Adenosine triphosphate (ATP) and creatine phosphate   Energy storage and metabolism
  Nucleic acids and nucleoproteins                      Genetic translation
  Phosphorylation of proteins                           Key regulatory mechanism; activation of enzymes, cell-signaling cascade
  2,3-Diphosphoglycerate                                Modulates oxygen release by hemoglobin
  Inorganic phosphate                                   Acid-base buffer

![**Phosphate metabolism and causes of hypophosphatemia**.](cc9215-1){#F1}

Hypophosphatemia can be caused by three different mechanisms \[[@B1],[@B2]\]: decreased intestinal absorption, increased renal excretion, or internal redistribution of inorganic phosphate (Figure [1](#F1){ref-type="fig"}). In most patients with severe hypophosphatemia, both depletion of total body phosphorus stores and redistribution of phosphate to the intracellular space are found. Decreased intestinal absorption of phosphate rarely causes hypophosphatemia, as a low-phosphate diet increases renal reabsorption and enhances intestinal uptake of phosphate. Still, malnutrition, diarrhea, and nasogastric suction are common features in critically ill patients.

Redistribution across the cell membrane is the most common cause of hypophosphatemia in ICU patients and can be caused by multiple clinical conditions \[[@B1],[@B3]\]: respiratory alkalosis-induced increase of intracellular pH causes phosphate to enter the cell by stimulating glycolysis \[[@B4]\]; administration of glucose and insulin also stimulates carbohydrate metabolism, during which phosphate is transported into the cells along with glucose; high serum levels of catecholamines such as epinephrine and norepinephrine, whether endogenous or exogenous, cause a decrease in serum phosphate \[[@B5]\]; cellular uptake of phosphate is increased under certain specific conditions such as the hungry-bone syndrome, and diseases with rapid cell proliferation such as acute leukemia; renal excretion of phosphate is increased by metabolic acidosis, and by many drugs, including diuretics, glucocorticoids \[[@B6]\], aminoglycosides, antiretroviral drugs, and anticancer drugs.

Serum phosphate levels are inversely correlated to levels of the inflammatory cytokines interleukin-6 and tumor necrosis factor-α \[[@B7]\]. The exact mechanism is unclear: renal phosphate excretion is very low in patients receiving interleukin therapy for cancer \[[@B8]\], suggesting that high interleukin levels cause internal redistribution of phosphate; hypophosphatemia may be caused by increased phosphate utilization by immune cells. Hypophosphatemia can be found in patients with severe infections, such as sepsis. Especially patients with Gram-negative bacteremia may develop hypophosphatemia \[[@B9]\]. Hypophosphatemia correlates to severity of illness and can even be used as a prognostic parameter in sepsis patients \[[@B10]\]. Infection with *Legionella*species is particularly associated with hypophosphatemia \[[@B11]\].

Hypophosphatemia often develops in the postoperative phase \[[@B12]-[@B15]\]. Multiple causal factors may be present, such as respiratory alkalosis, administration of insulin, and the use of diuretics. This is particularly true for major surgery, such as cardiac surgery and abdominal aortic surgery. The role of cardiopulmonary bypass is not clear. After major hepatic surgery, hypophosphatemia is extremely frequent. Reported mechanisms involve both shifts of phosphate into hepatocytes \[[@B16]\] and renal phosphate wasting \[[@B17]\]. Hypophosphatemia is reported to be more frequently encountered in trauma patients \[[@B18]\]. Renal phosphate handling is altered in trauma patients, resulting in inadequately increased urinary phosphate excretion. Hypophosphatemia is even more frequent in burn-wound victims, where phosphate is lost through the skin \[[@B19],[@B20]\]. In patients with head trauma, induction of polyuresis may be an aggravating factor \[[@B21]\].

In patients with malnutrition, a so-called refeeding syndrome may develop when they receive (par-)enteral feeding, a syndrome characterized by multiple metabolic abnormalities including depletion of total body phosphorus stores and redistribution of phosphate to the intracellular compartment, which may result in severe hypophosphatemia \[[@B22]\].

Hypothermia induces polyuresis and is associated with hypophosphatemia as well \[[@B23]\]. The use of (continuous) renal replacement therapy may lead to hypophosphatemia when low-phosphate replacement solution and dialysate are used. Patients who require high-flux dialysis for intoxications are especially at risk. Addition of potassium phosphate to dialysate and replacement fluids safely prevents the development of hypophosphatemia \[[@B24]\].

Finally, patients with diabetic ketoacidosis commonly present with hypophosphatemia due to increased urinary phosphate excretion. Phosphate levels generally decrease further during treatment because of intracellular shifting along with glucose and potassium \[[@B25]\].

Epidemiology of hypophosphatemia
--------------------------------

Table [2](#T2){ref-type="table"} summarizes the reported incidence and prevalence of hypophosphatemia in surgical and medical ICU patients \[[@B7],[@B12],[@B14],[@B15],[@B17]-[@B19],[@B21],[@B26]-[@B30]\]. Hypophosphatemia is usually categorized as moderate (serum phosphate level of 0.32 to 0.65 mmol/L (1 to 2 mg/dl) or severe (\<0.32 mmol/L (\<1 mg/dl)). In the general hospital population, the prevalence of moderate hypophosphatemia ranges between 2.2 and 3.1% \[[@B31],[@B32]\], and the prevalence of severe hypophosphatemia is reported to be 0.2 to 0.4% \[[@B32]-[@B34]\]. One study reports that 45% of all hospital hypophosphatemia cases occur in the ICU population \[[@B35]\]. Hypophosphatemia has a higher incidence in certain patient groups, such as patients with diabetic ketoacidosis, sepsis, and postoperative patients. Hypophosphatemia is found in as many as 34% of patients after elective cardiac surgery \[[@B12]\]. An extremely high incidence of hypophosphatemia is reported after major hepatic surgery, where almost all patients develop hypophosphatemia in the first postoperative week \[[@B17],[@B26]\]. In this group, serum phosphate levels decrease to a nadir within approximately 2 days and recover in the following days. This early nadir is also described after cardiac surgery and in patients with diabetic ketoacidosis and the refeeding syndrome. Trauma patients have a higher incidence of hypophosphatemia, especially patients with burn wounds \[[@B19]\] and head trauma \[[@B21]\]. Although the use of renal replacement therapy leads to hypophosphatemia, no epidemiologic reports were found.

###### 

Prevalence and/or incidence of hypophosphatemia

  Author \[ref.\]                       Year   Population/disease                  Number of patients   Definition of hypophosphatemia   Prevalence   Incidence
  ------------------------------------- ------ ----------------------------------- -------------------- -------------------------------- ------------ -----------
  Surgical ICU patients                                                                                                                               
                                                                                                                                                      
  Goldstein *et al.*\[[@B15]\]          1985   Thoracic surgery                    34                   \<0.80 mmol/L                    \-           56%
                                               Cardiac surgery                     40                   \<0.80 mmol/L                    \-           50%
  Zazzo *et al.*\[[@B14]\]              1995   Surgical ICU                        208                  \<0.80 mmol/L                    \-           28.8%
                                                                                                        ≤0.50 mmol/L                     \-           17.3%
                                                                                                        ≤0.20 mmol/L                     \-           2.4%
  Buell *et al.*\[[@B26]\]              1998   Hepatic surgery                     35                   \<0.80 mmol/L                    \-           67%
  Cohen *et al.*\[[@B12]\]              2004   Cardiac surgery                     566                  \<0.48 mmol/L                    \-           34.3%
  Salem *et al.*\[[@B17]\]              2005   Hepatic surgery                     20                   \<0.70 mmol/L                    \-           100%
                                                                                                                                                      
  Medical ICU patients                                                                                                                                
                                                                                                                                                      
  Daily *et al.*\[[@B18]\]              1990   Trauma patients                     12                   \<0.80 mmol/L                    \-           75%
                                                                                                        \<0.50 mmol/L                    \-           56%
  Kruse *et al.*\[[@B27]\]              1992   General ICU patients                418                  \<0.80 mmol/L                    \-           28%
  Marik *et al.*\[[@B28]\]              1996   Refeeding after \>48 h starvation   62                   \<0.65 mmol/L                    \-           34%
                                                                                                        \<0.32 mmol/L                    \-           6%
  Berger *et al.*\[[@B19]\]             1997   Burn injuries                       16                   \<0.80 mmol/L                    \-           100%
                                                                                                        \<0.30 mmol/L                    \-           50%
  Barak *et al.*\[[@B7]\]               1998   Sepsis                              99                   \<0.80 mmol/L                    80%          \-
                                               Infection without sepsis            32                   \<0.80 mmol/L                    65%          \-
                                               Sepsis, negative blood culture      37                   \<0.80 mmol/L                    80%          \-
                                               Sepsis, postive blood culture       30                   \<0.80 mmol/L                    80%          \-
  Polderman *et al.*\[[@B21]\]          2000   Head trauma                         18                   \<0.60 mmol/L                    61%          \-
  Milionis *et al.*\[[@B29]\]           2002   Severe heart failure                86                   \<0.77 mmol/L                    13%          \-
  Dominguez-Roldan *et al.*\[[@B30]\]   2005   Brain-dead patients                 50                   \<0.80 mmol/L                    \-           72%

Correction of hypophosphatemia, when encountered, is not reported in epidemiologic studies and the spontaneous course of serum phosphate levels without treatment is generally not addressed.

Symptoms of hypophosphatemia
----------------------------

Serum phosphate levels do not accurately reflect total body phosphorus stores; hence the degree of hypophosphatemia does not always correlate to the presence of symptoms. Although most patients with hypophosphatemia do not develop symptoms, fatal complications have been described. A common mechanism in hypophosphatemia-caused complications is impaired energy metabolism, leading to cellular dysfunction in multiple organ systems. Symptoms are summarized in Table [3](#T3){ref-type="table"}.

###### 

Symptoms of hypophosphatemia

  ----------------------------------------------
  **Respiratory**
  Respiratory muscle dysfunction
   Acute respiratory failure
   Failure to wean from mechanical ventilation
  Decreased peripheral oxygen delivery
  **Cardiovascular**
  Decreased myocardial contractility
   Acute heart failure
   Increased inotropic requirement
  Arrhythmia
   Ventricular tachycardia
   Supraventricular tachycardia
   Premature beats
  **Hematologic**
  Hemolysis
  Leukocyte dysfunction
  **Endocrine**
  Insulin resistance
  **Neuromuscular**
  Skeletal muscle weakness
  Rhabdomyolysis
  Polyneuropathy
  Altered mental status
  Seizures
  Encephalopathy
  Central pontine myelinolysis
  ----------------------------------------------

### Respiratory effects

Hypophosphatemia is associated with respiratory muscle dysfunction, potentially resulting in (acute) respiratory failure and weaning problems \[[@B36]-[@B38]\]. The mechanism is considered to be decreased availability of phosphate-containing energy sources. Depletion of 2,3- diphosphoglycerate (2,3-DPG) shifts the oxygen dissociation curve to the left, decreasing oxygen delivery to peripheral tissue \[[@B39],[@B40]\]. This might be especially relevant in patients with chronic pulmonary disease, as these patients may have higher 2,3-DPG levels to compensate for hypoxemia. In addition, hypophosphatemia has also been associated with decreased tissue oxygenation after correction for 2,3-DPG levels \[[@B41]\].

### Cardiovascular effects

Hypophosphatemia can lead to myocardial dysfunction and arrhythmias. Phosphate depletion causes impaired energy metabolism in the myocardium, leading to decreased contractility \[[@B42],[@B43]\]. Severe acute heart failure has been described in several case reports in the presence of severe hypophosphatemia. Hypophosphatemia after cardiac surgery was associated with higher requirements of inotropic support \[[@B12]\]. Correction of hypophosphatemia is associated with improved cardiac output \[[@B14]\]. Hypophosphatemia is a significant predictor of ventricular tachycardia after myocardial infarction \[[@B44]\] and a correlation with arrhythmias has been suggested in septic patients \[[@B45]\]. During correction of hypophosphatemia, phosphate may precipitate with calcium and cause hypocalcemia. It is important to keep in mind that hypocalcemia can negatively influence cardiac function as well.

### Other effects

Hypophosphatemia can cause hematologic dysfunction \[[@B46]-[@B48]\], insulin resistance \[[@B49]\], and a number of neuromuscular symptoms (Table [3](#T3){ref-type="table"}). Of the latter, rhabdomyolysis \[[@B50],[@B51]\] and central pontine myelinolysis \[[@B52],[@B53]\] are most severe. Besides hypophosphatemia, critically ill patients frequently have multiple factors putting them at risk for neurologic alterations, and causality is not well documented.

### Hypophosphatemia and mortality

Multiple studies show an association between hypophosphatemia and increased mortality \[[@B10],[@B12],[@B14],[@B35],[@B54]-[@B59]\]. Severe hypophosphatemia has been reported to predict up to eightfold increased mortality rate in sepsis patients \[[@B10]\]. However, hypophosphatemia has not been associated with increased mortality after cardiac surgery \[[@B12]\] and in diabetic ketoacidosis \[[@B54]\]. It remains unclear whether hypophosphatemia actually contributes to mortality, or merely is a marker for severity of illness. Whether correction of hypophosphatemia reduces mortality is currently unknown.

Correction of hypophosphatemia
------------------------------

With the high prevalence of hypophosphatemia in critically ill patients, as well as their susceptibility to life-threatening symptoms, frequent laboratory monitoring is recommended, especially in previously mentioned high-risk groups. It is generally recommended to correct hypophosphatemia in hypophosphatemic patients with associated symptoms \[[@B2],[@B60]\]. However, no randomized controlled evidence indicates whether correction of hypophosphatemia in apparently asymptomatic patients leads to improved outcome. Taking this into account, the indication for \-- and recommended frequency of \-- laboratory monitoring and treatment remains debatable.

Correction of hypophosphatemia is possible via oral or intravenous routes. Intravenous administration of phosphate is not without complications, though. Phosphate may precipitate with calcium. Large intravenous doses of phosphate may result in hyperphosphatemia, hypomagnesemia, hypocalcemia, and hypotension. It is therefore necessary to know when intravenous therapy is indicated, and how much and how fast phosphate should be supplied. Intravenous therapy is generally recommended in symptomatic hypophosphatemia and phosphate levels \<0.32 mmol/L. Multiple studies have evaluated the efficacy and safety of intravenous phosphate repletion regimens (Table [4](#T4){ref-type="table"}) \[[@B61]-[@B67]\]. These studies generally agree that aggressive phosphate supplementation is safe with phosphate doses up to 45 mmol with infusion rates up to 20 mmol per hour. Hyperkalemia is prevented by using sodium phosphate instead of potassium phosphate in patients with potassium levels \>4 mmol/L.

###### 

Intravenous treatment of hypophosphatemia

  Author \[ref.\]                Year   Serum phosphate (mmol/L)   Dose           Speed           Efficacy                               Complications/safety
  ------------------------------ ------ -------------------------- -------------- --------------- -------------------------------------- ----------------------------------------------
  Brown *et al.*\[[@B61]\]       2006   0.73-0.96                  0.32 mmol/kg   7.5 mmol/h      No significant increase in iP          Considered safe
                                        0.51-0.72                  0.64 mmol/kg   7.5 mmol/h      iP normalized in 59%                   Considered safe
                                        \<0.50                     1 mmol/kg      7.5 mmol/h      iP normalized in 60%                   Considered safe
  Taylor *et al.*\[[@B62]\]      2004   0.55-0.70                  0.2 mmol/kg    33 μmol/kg/h    iP normalized in 76% (all patients)    Considered safe
                                        0.32-0.55                  0.4 mmol/kg    67 μmol/kg/h                                           Considered safe
                                        \<0.32                     0.6 mmol/kg    100 μmol/kg/h                                          Considered safe
  Charron *et al.*\[[@B63]\]     2003   0.40-0.65                  30 mmol        15 mmol/h       Equally effective                      Mild hyperphosphatemia and mild hyperkalemia
                                                                   30 mmol        7.5 mmol/h                                             
                                        \<0.40                     45 mmol        15 mmol/h       Equally effective                      
                                                                   45 mmol        7.5 mmol/h                                             
  Perreault *et al.*\[[@B64]\]   1997   0.40-0.80                  15 mmol        5 mmol/h        iP normalized in 81.5%                 Considered safe
                                        \<0.40                     30 mmol        10 mmol/h       iP normalized in 30%                   Considered safe
  Rosen *et al.*\[[@B65]\]       1995   0.50-0.65                  15 mmol        7.5 mmol/h      iP normalized in 100%                  Considered safe
  Bollaert *et al.*\[[@B66]\]    1995   \<0.65                     20 mmol        20 mmol/h       iP normalized in 80%                   Considered safe Mild hypocalcemia
  Kruse *et al.*\[[@B67]\]       1992   \<0.80                     20-40 mmol     20 mmol/h       mean iP rose from 0.65 to 1.0 mmol/L   considered safe Mild hypocalcemia

iP, serum inorganic phosphate.

Moderate hypophosphatemia can be treated with oral supplementation of phosphate. One should keep in mind that active vitamin D is required for intestinal absorption of phosphate. Typical oral supplementation amounts are three times the normal daily intake, with advised amounts of 2.5 to 3.5 g (80 to 110 mmol) per day, divided over two to three doses. Patients who receive feeding after a period of starvation are often phosphate depleted, so additional phosphate should be added to nutritional preparations. An additional preventive strategy is to build up the caloric intake slowly \[[@B22]\]. The total required amount of phosphate cannot be predicted by serum phosphate levels, as phosphate shifts between multiple body compartments.

Dipyridamole can decrease urinary phosphate loss \[[@B68]\]. Further research is needed to establish further the role of this drug in the treatment of hypophosphatemia in critically ill patients.

Discussion
==========

Critically ill patients have a high prevalence of hypophosphatemia because of the presence of multiple causal factors. Hypophosphatemia may lead to a multitude of symptoms, but most often remains asymptomatic. Hypophosphatemia, however, is associated with increased mortality in important patient subgroups. It is important to investigate whether hypophosphatemia causes higher mortality in itself, or rather is associated with a higher severity of illness.

Because of the current paucity of evidence, serum phosphate levels are not routinely measured in all critically ill patients. The spontaneous course of serum phosphate is not well documented in the literature, so it is insufficiently clear whether an initially low phosphate level after surgery will return to normal spontaneously. Although multiple studies have evaluated the efficacy and safety of phosphate repletion regimens, the effect on mortality and morbidity is not well reported. Currently, no widely agreed-on guidelines exist concerning the approach to hypophosphatemia in critically ill patients, because evidence is lacking on when and how to treat hypophosphatemia.

A reasonable approach awaiting randomized controlled trial evidence would be to reserve intravenous correction of hypophosphatemia for patients with associated symptoms or phosphate levels \<0.32 mmol/L. Doses of up to 40 mmol of sodium phosphate, administered at a speed of up to 20 mmol per hour, are proven to be safe. Additional studies are required, addressing the current approach to hypophosphatemia in critically ill patients, as well as the association of hypophosphatemia with morbidity and mortality, and the effect of treatment. Evidence-based guidelines are needed to guide critical care physicians in the diagnosis and treatment of hypophosphatemia.

Conclusions
===========

Additional studies are required to address the current approach to hypophosphatemia in critically ill patients, as well as the association of hypophosphatemia with morbidity and mortality, and the effect of the correction of this electrolyte disorder.

Key messages
============

• Critically ill patients have a high prevalence of hypophosphatemia because of the presence of multiple causal factors.

• Hypophosphatemia may lead to a multitude of symptoms, including cardiac and respiratory failure, and is associated with higher mortality.

• Although multiple studies confirm the efficacy and safety of intravenous phosphate administration, it is unknown which treatment strategy is superior.

• Nevertheless, correction of hypophosphatemia has not been shown to improve outcome.
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